<DOC>
	<DOCNO>NCT00995293</DOCNO>
	<brief_summary>The Primary Objective evaluate progression-free survival treatment docetaxel plus cisplatin plus 5-Fluorouracil ( 5-FU ) ( DCF ) comparison cisplatin plus 5-FU ( CF ) patient locally advance inoperable SCCHN The Secondary Objective evaluate compare clinical response rate radiotherapy , local symptom , duration response , time treatment failure , survival , toxicity quality life 2 study group .</brief_summary>
	<brief_title>Taxotere ( Docetaxel ) New Indication : Squamous Cell Carcinoma Head Neck ( SCCHN ) Treatment Registration Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion criterion : Tumor type : Histologically cytologically proven squamous cell carcinoma head neck ( SCCHN ) present locally advanced disease diagnosis . Primary tumor site eligible : oral cavity , oropharynx , hypopharynx larynx . Extent disease : Patients require least one measurable lesion . Stage III IV without evidence distant metastasis , accord TNM staging system . Absence metastasis must check chest Xray ( without Computed tomography ( CT ) ) , abdominal ultrasound CT case liver function test abnormality , bone scan case local symptom . Tumor consider inoperable evaluation multidisciplinary team . Reason inoperability report CRF World Health Organization ( WHO ) performance status 0 1 Laboratory data : Haematology : Neutrophil count &gt; = 2.0*10^9/L Platelet count &gt; = 100*10^9/L Hemoglobin &gt; = 10 g/dl ( 6.2 mmol/L ) Hepatic function : Total serum bilirubin &lt; = 1 time upper normal limit ( UNL ) participate center Aspartate transaminase ( ASAT/SGOT ) Alanine transaminase ( ALAT/SGPT ) &lt; = 2.5UNL Alkaline phosphatase &lt; = 5 UNL Patients ASAT ALAT &gt; 1.5UNL associated alkaline phosphatase &gt; 2.5UNL eligible study Renal function : serum creatinine &lt; = 120µmol/L ( 1.4 mg/dl ) value &gt; 120µmol/L , creatinine clearance &gt; = 60 ml/min Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule , condition discuss patient registration trial Patients inform consent form obtain Exclusion criterion : Tumors nasopharynx , nasal paranasal cavity . Previous chemotherapy radiotherapy reason previous surgery SCCHN time study entry . Prior treatment within therapeutic clinical tria within 30 day prior study entry Concurrent treatment anticancer therapy Chronic treatment ( &gt; = 3 month ) corticosteroid daily dose &gt; = 20mg methylprednisolone equivalent . Concomitant use drug could interact 5fluorouracil ( e.g . cimetidine , allopurinol , folic folinic acid , methotrexate metronidazole ) Previous current malignancy sit exception adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma skin cancer curatively treat surgery evidence disease least 5 year Symptomatic peripheral neuropathy &gt; = grade 2 NCICCTG criterion Clinical alter hearing Pregnant , lactate woman childbearing potential unless adequate serious illness medical condition include limited : unstable cardiac disease despite treatment myocardial infarction within 6 month prior study entry history significant neurologic psychiatric disorder include dementia seizure active uncontrolled infection active peptic ulcer chronic obstructive pulmonary disease require hospitalization year precede study entry The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>